Is Collegium Pharmaceutical (COLL) One of the Best Small-Cap Drug Manufacturers

Collegium Pharmaceutical Inc. (NASDAQ:COLL) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds.

On March 24, Vikram Karnani, President and CEO at Collegium Pharmaceutical Inc. (NASDAQ:COLL), shared his views on the company’s recent agreement with Corium Therapeutics Holdings for the acquisition of AZSTARYS. The deal involves $650 million in cash payments, along with earn-out considerations that could reach $135 million.

pikselstock/Shutterstock.com

Karnani emphasized that this transaction will enable the company to further diversify its topline, beyond the pain medicines category. He also highlighted that it will continue to contribute to the company’s revenue base through to the late 2030s, further strengthening Collegium’s presence within the ADHD space. Given the company’s existing operational and marketing capabilities within ADHD, this addition will lead to expanded margins and higher operating leverage.

On February 23, Boston Legacy FC named Collegium Pharmaceutical Inc. (NASDAQ:COLL) an official partner and announced a multi-year partnership with the company. Boston Legacy FC and Collegium are collaborating to make the club’s home games more comfortable and inclusive for fans.

Under this partnership, the Collegium Sensory Room at Gillette, Centreville, and White Stadium will be made available for all Boston Legacy FC home matches in 2027. The sensory room is a specific area designed to give fans and visitors a more peaceful and safer environment away from the intense visual and acoustic aspects experienced during the match, thus enhancing the experience of the visitors and making it more pleasurable and comfortable.

Collegium Pharmaceutical Inc. (NASDAQ:COLL) focuses on the development and commercialization of pain management medicines. It offers a wide range of products, which include Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR, and Symproic.

While we acknowledge the risk and potential of COLL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than COLL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.